189 related articles for article (PubMed ID: 9797797)
1. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
2. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
4. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
7. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
8. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
9. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
10. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of two selegiline hydrochloride tablet products.
Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
[TBL] [Abstract][Full Text] [Related]
15. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine.
Melega WP; Cho AK; Schmitz D; Kuczenski R; Segal DS
J Pharmacol Exp Ther; 1999 Feb; 288(2):752-8. PubMed ID: 9918585
[TBL] [Abstract][Full Text] [Related]
16. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
18. Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Anttila M; Sotaniemi EA; Pelkonen O; Rautio A
Clin Pharmacol Ther; 2005 Jan; 77(1):54-62. PubMed ID: 15637531
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
20. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma.
Szebeni G; Lengyel J; Székács G; Magyar K; Gaál J; Szatmári I
Acta Physiol Hung; 1995; 83(2):135-41. PubMed ID: 8588500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
